Browsing Tag
National Medical Products Administration
29 posts
GSK’s $1.7bn Hansoh licence looks better after Ris-Rez delivers 18.5-month survival in Phase III lung cancer trial
Hansoh Pharmaceutical Group's risvutatug rezetecan produced median overall survival of 18.5 months against 10.3 months for topotecan, strengthening an asset for which GSK paid $185 million upfront and committed up to $1.525 billion in milestones.
Roche’s $570m MediLink bet gets Phase III validation as Tam-Peli cuts small-cell lung cancer death risk by 54%
MediLink Therapeutics' Tam-Peli improved median survival to 13.3 months from 9.4 months in relapsed small-cell lung cancer, giving Roche stronger clinical support for a programme that already carries $570 million of upfront and near-term economics.
Gan & Lee Pharmaceuticals doses first participant with once-weekly oral GLP-1 candidate
Gan & Lee Pharmaceuticals has dosed the first participant in a 112-person Phase I study of GZC8072, an oral peptide GLP-1 receptor agonist designed for once-weekly administration, putting pharmacokinetics and tolerability ahead of any near-term weight-loss claims.
Glaucoma drug NCX 470 reaches another major market as Nicox’s partner strategy pays off
NCX 470 enters China review as Nicox targets glaucoma royalties across China, the U.S. and Japan. See what the filing means for growth.
Nuvectis Pharma’s ciprocopan approval validates its Haisco deal but raises the execution stakes
Nuvectis Pharma gains ciprocopan validation in China, but licensing costs, dilution and ex-China execution will determine its real value.
Aligos receives $25m Amoytop payment as China HBV catalyst strengthens
Aligos receives $25 million from Amoytop as China grants breakthrough status to its HBV drug. Read how the deal reshapes ALGS cash runway and strategy.
Akeso gumokimab approval strengthens China biologics push as psoriasis market heats up
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and boost its autoimmune drug strategy.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Biogen (BIIB) buys felzartamab rights in China from TJ Biopharma for up to $850m, completing global ownership
Biogen pays $100M upfront for felzartamab's China rights from TJ Biopharma, completing global ownership of the CD38 antibody with up to $850M at stake. Read the full analysis.
Why BeOne Medicines (ONC) just strengthened its China oncology play with Imdelltra approval
BeOne Medicines wins China approval for Amgen’s Imdelltra in lung cancer. Read why this matters for ONC, competition, and China oncology growth.